With over 10,000 deals and alliances completed in the past five years, the USA is an essential target market for the company and Jim will be responsible for expanding its share of the market.
McCarthy brings with him a wealth of experience including the start-up of strategic therapeutic business units, pharmaceutical marketing, new products introductions and the life cycle management of established products in the oncology, central nervous system and cardiovascular fields.
Essential for his new role, McCarthy’s work has reached over 30 countries and has covered a range of external growth alliance targets; acquisitions, divestments, licensing, research and agreements. He has worked with some highly respected companies such as Bristol-Myers Squibb, Technology Innovations, Eli Lily & Company and the Arthur Young Health Care Consulting Group.
Fintan Walton, CEO of PharmaVentures said; “The USA is the world’s largest player in the pharmaceutical industry and with over 50% of our business already coming from the USA, it is essential that we maximise on its continued growth. Jim’s appointment will further strengthen our existing position in the country; we already have offices in San Francisco and Cincinnati. He has an outstanding and successful business track record, working in fields such as pharmaceuticals, medical device and ethical nutrition.”
- ends -